Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Lingotto Investment Management LLP’s 2nd Largest Position

Lingotto Investment Management LLP increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 27,192,388 shares of the company’s stock after buying an additional 688,862 shares during the quarter. Teva Pharmaceutical Industries comprises approximately 16.1% of Lingotto Investment Management LLP’s portfolio, making the stock its 2nd largest position. Lingotto Investment Management LLP owned about 2.40% of Teva Pharmaceutical Industries worth $599,320,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Smithfield Trust Co raised its position in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth about $50,000. Venturi Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $60,000. Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $66,000. Finally, Farther Finance Advisors LLC raised its position in Teva Pharmaceutical Industries by 273.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after purchasing an additional 3,323 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.55% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TEVA. Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Teva Pharmaceutical Industries Trading Down 1.1 %

Shares of TEVA stock opened at $16.59 on Wednesday. The business’s fifty day moving average price is $19.93 and its 200 day moving average price is $18.50. The firm has a market capitalization of $18.79 billion, a PE ratio of -11.44, a P/E/G ratio of 1.44 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.